National Advisory Committee on Immunization (NACI): Statements and publications
NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable diseases for whom vaccination should be targeted. NACI knowledge syntheses, analyses and recommendations on vaccine use in Canada are published in literature reviews, statements and updates.
New statements are those which have been published within the past five years. Previous statements are those which are were published over five years ago and have been archived.
NACI recommendations are also published in vaccine-specific chapters of the Canadian Immunization Guide. Email updates are available through our mailing list.
Bacille Calmette Guérin (BCG) Vaccine
Canadian Immunization Guide (CIG) chapter
New statements
- None
Previous statements
COVID-19
Canadian Immunization Guide (CIG) chapter
Previous summaries of updates in the CIG
- Archive 40: Summary of updates in the Canadian Immunization Guide: Updated guidance on COVID-19 vaccines in Canada [2022-08-29]
- Archive 38: Summary of updates in the Canadian Immunization Guide: Updated guidance on COVID-19 vaccines in Canada [2022-06-21]
- Archive 30: Summary of updates in the Canadian Immunization Guide: Updated guidance on COVID-19 vaccines in Canada [2022-06-03]
- Archive 28: Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis) [2022-01-14]
- Archive 27: Summary of the COVID-19 vaccine chapter in the Canadian Immunization Guide [2021-12-23]
Current vaccine statements
- March 3, 2023: Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19
- January 20, 2023: Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023
- December 9, 2022: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration
NACI updates recommendations on the use of authorized COVID-19 vaccines as:
- Health Canada approves vaccines for use in Canada
- evidence on these vaccines and COVID-19 evolves
Previous statements
- Archived 47: Summary of NACI updates: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults [2022-11-03]
- Archived 46: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age [2022-10-21]
- Archived 45: Updated guidance on COVID-19 vaccine booster doses in Canada [2022-10-07]
- Archived 44: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding [2022-09-09]
- Archived 43: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age [2022-08-19]
- Archived 42: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age [2022-07-14]
- Archived 41: Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada [2022-06-29]
- Archived 39: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines [2022-09-01]
- Archived 37: Updated guidance on a first booster dose of COVID-19 vaccines in Canada [2022-04-12]
- Archived 36: Initial guidance on a second booster dose of COVID-19 vaccines in Canada [2022-04-05]
- Archived 35: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age [2022-03-17]
- Archived 34: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz) [2022-03-11]
- Archived 33: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine [2022-02-17]
- Archived 32: NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [2022-02-04]
- Archived 31: NACI rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age [2022-01-28]
- Archived 29: Updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age [2022-01-25]
- Archived 26: Updated guidance on booster COVID-19 vaccine doses in Canada [2021-12-03]
- Archived 25: NACI rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [2021-12-03]
- Archived 24: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10mcg) in children 5 to 11 years of age [2021-11-19]
- Archived 23: Table of updates: Recommendations on the use of COVID-19 vaccines [2020-12-20 to 2021-10-22]
- Archived 22: Recommendations on the use of COVID-19 vaccines [2021-10-22]
- Archived 21: NACI interim guidance on booster COVID-19 vaccine doses in Canada [2021-10-29]
- Archived 20: NACI rapid response: Booster dose of COVID-19 vaccine in long-term care residents and seniors living in other congregate settings [2021-09-28]
- Archived 19: NACI rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following a 1- or 2-dose primary series [2021-09-10]
- Archived 18: Recommendation on the use mRNA COVID-19 vaccines in adolescents 12 to 17 years of age [2021-08-27]
- Archived 17: Recommendations on the use of COVID-19 vaccines [2021-09-28]
- Archived 16: Recommendations on the use of COVID-19 vaccines [2021-07-22]
- Archived 15: Recommendations on the use of COVID-19 vaccines [2021-07-02]
- Archived 14: Recommendations on the use of COVID-19 vaccines [2021-06-17]
- Archived 13: Recommendations on the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 18 years of age [2021-05-18]
- Archived 12: NACI rapid response: Interchangeability of authorized COVID-19 vaccines [2021-06-01]
- Archived 11: Recommendations on the use of COVID-19 vaccines [2021-05-28]
- Archived 10: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply [2021-04-07]
- Archived 9: Recommendations on the use of COVID-19 vaccines [2021-05-03]
- Archived 8: NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults [2021-03-29]
- Archived 7: Recommendations on the use of COVID-19 vaccines [2021-04-23]
- Archived 6: Recommendations on the use of COVID-19 vaccines [2021-03-16]
- Archived 5: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada [2021-03-03]
- Archived 4: Recommendations on the use of COVID-19 vaccines [2021-03-01]
- Archived 3: Recommendations on the use of COVID-19 vaccines [2021-01-12]
- Archived 2: Recommendations on the use of COVID-19 vaccines [2020-12-23]
- Archived 1: Recommendations on the use of COVID-19 vaccine(s) [2020-12-12]
Prioritization statements
- Archived: Guidance on the prioritization of key populations for COVID-19 immunization [2021-02-12]
- Archived: Guidance on the prioritization of initial doses of COVID-19 vaccine(s) [2020-12-18]
- Archived: Preliminary guidance on key populations for early COVID-19 immunization [2020-11-03]
Research priorities statement
- Archived: Research priorities for COVID-19 vaccines to support public health decisions [2020-07-15]
- Refer to the current vaccine statement for research priorities.
Guidance documents
- November 2021: Guidance on the use of influenza vaccine in the presence of COVID-19
- October 2020: Recommendations on the Duration of the Post-vaccination Observation Period for Influenza Vaccination during the COVID-19 Pandemic
- August 2020: Archived: Guidance for influenza vaccine delivery in the presence of COVID-19 [2021-08-05]
- May 2020: Interim guidance on continuity of immunization programs during the COVID-19 pandemic
Diphtheria Toxoid
Canadian Immunization Guide (CIG) chapter
New statements
- 2018 - Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
- Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
- CCDR - Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
Previous statements
- 2014 - Statement on the booster for 4-6 year-olds for protection against pertussis
- 2014 - Update on pertussis vaccination in pregnancy
- 2007 - Statement on the recommended use of pentavalent and hexavalent vaccines
- 2005 - Interval between administration of vaccines against diphtheria, tetanus, and pertussis
- 2005 - Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age
- 2003 - Prevention of pertussis in adolescents and adults
- 2000 - Statement on adult/adolescent formulation of combined acellular pertussis, tetanus and diphtheria vaccine
Haemophilus influenzae Type B (Hib) Vaccine
Canadian Immunization Guide (CIG) chapter
New statements
- None
Previous statements
Hepatitis Vaccines
Canadian Immunization Guide (CIG) chapters
New statements
- 2017 - Update on the recommended use of hepatitis B vaccine
- 2016 - Update on the recommended use of hepatitis A vaccine
Previous statements
- 2007 - Statement on the recommended use of pentavalent and hexavalent vaccine
- 2001 - Update on Hepatitis A vaccine (AVAXIM®, Aventis Pasteur)
- 2000 - Supplementary statement on hepatitis A vaccine
- 2000 - Statement on alternate adolescent schedule for hepatitis B
- 1999 - Supplementary statement on hepatitis prevention - hepatitis A and hepatitis B combination vaccine for children
- 1999 - Statement on combination vaccines against hepatitis A and hepatitis B
Herpes Zoster (Shingles) Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
Previous statements
Human Papillomavirus (HPV) Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- 2017 - Updated recommendations on human papillomavirus (HPV) vaccine: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations
- 2016 - Updated recommendations on human papillomavirus vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule
- 2015 - Update on the recommended human papillomavirus (HPV) vaccine immunization schedule
Influenza Vaccines
Current statement
Guidance documents
- February 2023: Guidance on the use of influenza vaccine in the presence of COVID-19
- Archived: August 2020: Guidance for influenza vaccine delivery in the presence of COVID-19 (2021-08-05)
New statements
- Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2022-2023
- CCDR - Summary of the NACI seasonal influenza vaccine statement for 2022–2023
- Recombinant influenza vaccines: A supplemental statement of the Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2022-2023
- Recommendation on repeated seasonal influenza vaccination
- Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2021-2022
- Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2020-2021
- CCDR - Summary of the NACI seasonal influenza vaccine statement for 2020–2021
- Recommendation on the use of live attenuated influenza vaccine (LAIV) in HIV-infected individuals
- Supplemental statement - Mammalian cell culture-based influenza vaccines - An Advisory Committee statement (2020-21)
- Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic
- Recommendations on fractional influenza vaccine dosing
- CCDR - Pandemic Preparedness: Summary of the NACI recommendations on fractional influenza vaccine dosing in the event of a shortage
- Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2019-2020
Previous statements
- Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2018-2019
- CCDR - Summary of the NACI seasonal influenza vaccine statement for 2018-2019
- Literature review on individuals with neurologic or neurodevelopment conditions and risk of serious influenza-related complications (2018)
- Literature review update on the efficacy and effectiveness of high-dose (Fluzone®High-Dose) and MF-59-adjuvanted (Fluad®) trivalent inactivated influenza vaccines in adults 65 years of age and older (2018)
- Supplemental statement - Afluria Tetra®- An advisory committee statement (ACS) (2018)
- Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2017-18
- 2016 - Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2016-17
- 2016 - Literature review of high dose seasonal influenza vaccine for adults 65 years and older
- 2015 - Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2015-16
- 2015 - Opinion on live attenuated influenza vaccine (LAIV) effectiveness in young children
- 2014 - Influenza vaccine effectiveness, immunogenicity, and safety in health adults 19-64 years old
- 2014 - Literature review on influenza vaccination in healthy 5-18 year olds
- 2014 - Literature review on quadrivalent influenza vaccines
- 2014 - Statement on seasonal influenza vaccine for 2014-15
- 2013 - Statement on seasonal influenza vaccine for 2013-14
- 2012 - Statement on seasonal influenza vaccine for 2012-13
- 2011 - Statement on seasonal influenza vaccine for 2011-12
- 2010 - Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2010-2011
- 2009 - Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2009-2010
- 2008 - Statement on influenza vaccination for the 2008-2009 season
- 2007 - Statement on influenza vaccination for the 2007-2008 season
- 2006 - Statement on influenza vaccination for the 2006-2007 season
- 2005 - Statement on influenza vaccination for the 2005-2006 season
- 2004 - Statement on influenza vaccination for the 2004-2005 season
- 2003 - Statement on influenza vaccination for the 2003-2004 season
- 2002 - Statement on influenza vaccination for the 2002-2003 season
- 2001 - Statement on influenza vaccination for the 2001-2002 season
- 2000 - Statement on influenza vaccination for the 2000-2001 season
Measles Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- 2018 - CCDR - Updated NACI recommendations for measles post-exposure prophylaxis
- 2016 - Update on measles-mumps-rubella-varicella vaccine and febrile seizures
Previous statements
- 2010 - Statement on measles-mumps-rubella-varicella vaccine
- 2010 - Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals
- 1998 - Measles Surveillance: Guidelines for Laboratory Support
- 1996 - Interim advisory on measles revaccination of persons with Acquired Immunodeficiency Syndrome (AIDS)
- 1996 - Supplementary statement on measles elimination in Canada
- 1996 - Supplementary statement on MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens
- 1995 - Guidelines for control of measles outbreaks in Canada
Meningococcal Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- 2020 - The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease
- 2015 - Update on quadrivalent meningococcal vaccines available in Canada
Previous statements
- 2014 - Advice for the use of the multicomponent meningococcal serogroup B (4CMenB) vaccine
- 2013 - Update on the use of quadrivalent conjugate meningococcal vaccines
- 2009 - Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations
- 2007 - Meningococcal C conjugate for infants statement
- 2007 - Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135
- 2005 - Update on meningococcal C conjugate vaccines
- 2003 - Supplementary statement on conjugate meningococcal vaccines
- 2001 - Statement on the recommended use of meningococcal vaccines
Mumps Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- 2021 - Use of Measles-Mumps-RUBELLA (MMR) Vaccine for the Management of Mumps Outbreaks in Canada
- 2016 - Update on measles-mumps-rubella-varicella vaccine and febrile seizures
Previous statements
- 2010 - Statement on measles-mumps-rubella-varicella vaccine
- 2010 - Guidelines for the prevention and control of mumps outbreaks in Canada
- 2010 - Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals
- 2007 - Statement on mumps vaccine
- 1996 - Supplementary statement on MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens
Pertussis Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- 2018 - Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
- Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
- CCDR - Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
Previous statements
- 2014 - Statement on the booster for 4-6 year-olds for protection against pertussis
- 2014 - Update on pertussis vaccination in pregnancy
- 2007 - Statement on the recommended use of pentavalent and hexavalent vaccines
- 2005 - Interval between administration of vaccines against diphtheria, tetanus, and pertussis
- 2005 - Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age
- 2003 - Prevention of pertussis in adolescents and adults
- 2000 - Statement on adult/adolescent formulation of combined acellular pertussis, tetanus and diphtheria vaccine
Pneumococcal Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- March 21, 2023 - Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations
- February 24, 2023 - Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines
- Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix
- Summary of National Advisory Committee on Immunization (NACI) Statement of February 2023: Public Health Level Recommendations on the Use of Pneumococcal Vaccines in Adults, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines
- 2018 - Update on the use of pneumococcal vaccines in adults 65 years of age and older - A public health perspective
- 2016 - Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older - Interim recommendation
- 2015 - Re-immunization with polysaccharide 23-valent pneumococcal vaccine (PNEU-P-23)
Previous statements
- 2014 - Update on the use of pneumococcal vaccines: Addition of asthma as a high-risk condition
- 2013 - Statement on the use of conjugate pneumococcal vaccine - 13 valent in adults (PNEU-C-13)
- 2010 - Update on the use of conjugate pneumococcal vaccines in childhood
- 2010 - Update on pediatric invasive pneumococcal disease and recommended use of conjugate pneumococcal vaccines
- 2008 - Statement on the recommended use of pneumococcal 23-valent polysaccharide vaccine in homeless persons and injection drug users
- 2006 - Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants
- 2004 - Recommendations for use of pneumococcal 23-valent polysaccharide vaccine during shortage
- 2002 - Statement on the recommended use of pneumococcal conjugate vaccine
Poliomyelitis Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- None
Previous statements
Rabies Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- None
Previous statements
Respiratory Syncytial Virus
Canadian Immunization Guide (CIG) chapter
New statements
- June 1, 2022: Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants
Previous statements
Rotavirus Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
Rubella Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
Smallpox and Monkeypox Vaccines
On November 28, 2022, the World Health Organization began using ‘mpox’ as the preferred term for monkeypox disease. We’ll be updating our content to reflect this change.
Canadian Immunization Guide (CIG) chapter
New statements
- September 23, 2022: NACI Rapid Response: Updated interim guidance on Imvamune in the context of ongoing monkeypox outbreaks
- June 10, 2022: NACI Rapid Response: Interim Guidance on the Use of Imvamune in the Context of Monkeypox Outbreaks in Canada
Previous statements
Tetanus Toxoid
Canadian Immunization Guide (CIG) chapter
New statements
- 2018 - Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
- Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
- CCDR - Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
Previous statements
- 2014 - Statement on the booster for 4-6 year-olds for protection against pertussis
- 2014 - Update on pertussis vaccination in pregnancy
- 2007 - Statement on the recommended use of pentavalent and hexavalent vaccines
- 2005 - Interval between administration of vaccines against diphtheria, tetanus, and pertussis
- 2005 - Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age
- 2003 - Prevention of pertussis in adolescents and adults
- 2000 - Statement on adult/adolescent formulation of combined acellular pertussis, tetanus and diphtheria vaccine
Varicella (Chickenpox) Vaccines
Canadian Immunization Guide (CIG) chapter
New statements
- 2016 - Updated recommendations for the use of varicella zoster immune globulin (VarIg) for the prevention of varicella in at-risk patients
- 2015 - Varicella proof of immunity - 2015 update
Previous statements
- 2010 - Varicella vaccination two-dose recommendations
- 2010 - Statement on measles-mumps-rubella-varicella vaccine
- 2010 - Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals
- 2006 - Varizig™ as the varicella zoster immune globulin for the prevention of varicella in at-risk patients
- 2004 - Update on varicella
- 2002 - NACI update to statement on varicella vaccine
- 1999 - Statement on recommended use of varicella virus vaccine
Other
New statements
Previous statements
- 2007 - Thimerosal: Updated statement
- 2005 - Updated recommendations on the use of thimerosal-containing vaccines in Canada
- 2003 - Statement on thimerosal
- 2003 - Immunization for cochlear implant recipients
- 2003 - Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab)
- 2000 - Statement on immunization for Lyme disease
- 1999 - Thimerosal in vaccines
Report a problem or mistake on this page
- Date modified: